DBV Technologies to Incorporate FDA Feedback on Patch for Treat Peanut Allergies

Dow Jones

06/30

DBV Technologies is working to incorporate feedback from the Food and Drug Administration before seeking marketing approval for a patch to treat peanut allergies.

The biopharmaceutical company said Monday it has had continuing discussions with the FDA in recent weeks to prepare to submit a Biologics License Application for its Viaskin Peanut Patch for children ages four through seven years.

During their collaboration, the FDA provided valuable input and has not requested additional information, DBV said. The company now expects to file its application for the treatment in the third quarter.

The patch is designed to introduce microgram amounts of a biologically active compound to the immune system through the skin to address peanut allergies.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

June 29, 2026 16:25 ET (20:25 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2647630288"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2647630288\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2647630288?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-30 04:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2647630288","market":"hk","top_or_hot":-1,"title":"DBV Technologies to Incorporate FDA Feedback on Patch for Treat Peanut Allergies","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/DBVT\">DBV Technologies</a> is working to incorporate feedback from the Food and Drug Administration before seeking marketing approval for a patch to treat peanut allergies. \n</p>\n<p>\n  The biopharmaceutical company said Monday it has had continuing discussions with the FDA in recent weeks to prepare to submit a Biologics License Application for its Viaskin Peanut Patch for children ages four through seven years. \n</p>\n<p>\n  During their collaboration, the FDA provided valuable input and has not requested additional information, DBV said. The company now expects to file its application for the treatment in the third quarter. \n</p>\n<p>\n  The patch is designed to introduce microgram amounts of a biologically active compound to the immune system through the skin to address peanut allergies. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 29, 2026 16:25 ET (20:25 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>DBV Technologies to Incorporate FDA Feedback on Patch for Treat Peanut Allergies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDBV Technologies to Incorporate FDA Feedback on Patch for Treat Peanut Allergies\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-06-30 04:25</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/DBVT\">DBV Technologies</a> is working to incorporate feedback from the Food and Drug Administration before seeking marketing approval for a patch to treat peanut allergies. \n</p>\n<p>\n  The biopharmaceutical company said Monday it has had continuing discussions with the FDA in recent weeks to prepare to submit a Biologics License Application for its Viaskin Peanut Patch for children ages four through seven years. \n</p>\n<p>\n  During their collaboration, the FDA provided valuable input and has not requested additional information, DBV said. The company now expects to file its application for the treatment in the third quarter. \n</p>\n<p>\n  The patch is designed to introduce microgram amounts of a biologically active compound to the immune system through the skin to address peanut allergies. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 29, 2026 16:25 ET (20:25 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2647630288","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2647630288","pubTimestamp":1782764700,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"DBV Technologies is working to incorporate feedback from the Food and Drug Administration before seeking marketing approval for a patch to treat peanut allergies.The biopharmaceutical company said Monday it has had continuing discussions with the FDA in recent weeks to prepare to submit a Biologics License Application for its Viaskin Peanut Patch for children ages four through seven years.During their collaboration, the FDA provided valuable input and has not requested additional information, DBV said. The company now expects to file its application for the treatment in the third quarter.The patch is designed to introduce microgram amounts of a biologically active compound to the immune system through the skin to address peanut allergies.Write to Kelly Cloonan at kelly.cloonan@wsj.com Dow Jones NewswiresJune 29, 2026 16:25 ET Copyright  2026 Dow Jones & Company, Inc.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4585":"ETF&股票定投概念","LABU":"三倍做多标普生物-Direxion","BK4139":"生物科技","DBV":"Invesco DB G10 Currency Harvest Fund","DBVT":"DBV Technologies S.A."},"translate_title":"DBV Technologies将纳入FDA对治疗花生过敏贴剂的反馈","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DBVT":0.9,"LABU":1.5,"DBV":1.5},"content_text":"DBV Technologies is working to incorporate feedback from the Food and Drug Administration before seeking marketing approval for a patch to treat peanut allergies. \n\n\n  The biopharmaceutical company said Monday it has had continuing discussions with the FDA in recent weeks to prepare to submit a Biologics License Application for its Viaskin Peanut Patch for children ages four through seven years. \n\n\n  During their collaboration, the FDA provided valuable input and has not requested additional information, DBV said. The company now expects to file its application for the treatment in the third quarter. \n\n\n  The patch is designed to introduce microgram amounts of a biologically active compound to the immune system through the skin to address peanut allergies. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 29, 2026 16:25 ET (20:25 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}